CART CELL THERAPY TOXICITY

Course overview

CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELL THERAPY IS AN EVOLVING TREATMENT ENTITY USED TO TREAT RELAPSED/REFRACTORY CANCERS. IT INVOLVES GENETICALLY MODIFYING AUTOLOGOUS OR ALLOGENEIC T CELLS TO EXPRESS CHIMERIC ANTIGEN RECEPTOR (CAR) PROTEINS THAT TARGET SPECIFIC CANCER CELLS. DESPITE PROMISING OUTCOMES, THESE CELLS ATTACK NORMAL TISSUE CELLS EXPRESSING SIMILAR PROTEINS ON THEIR SURFACES. THIS CROSS-REACTIVITY RESULTS IN ADVERSE EVENTS (AES), LEADING TO SUBSTANTIAL MORTALITY AND MORBIDITY. THIS ACTIVITY REVIEWS THE EVALUATION AND TREATMENT OF CAR-T TOXICITY AND HIGHLIGHTS THE ROLE OF INTERPROFESSIONAL TEAMS IN EVALUATING AND TREATING PATIENTS WITH THESE AES.